English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.

A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study